Merck has scooped up worldwide rights to Endocyte's ($ECYT) late-stage ovarian cancer drug in a billion-dollar deal, paying $120 million upfront and committing up to $880 million in milestones. And West Lafayette, IN-based Endocyte will also get co-promotion rights and a split of U.S. profits while earning double-digit royalties in the rest of the world.
Investors liked the sound of big round numbers, bidding up Endocyte shares by 111% once the news hit.
Merck ($MRK) says the drug--Vintafolide, or EC145--matches the profile of what it's looking for in a cancer drug, highlighting Endocyte's development of a companion diagnostic to identify patients most likely to respond to the treatment. And Endocyte says it's only months away from filing for U.S. approval. The treatment has been given orphan drug status in Europe...
-----------------
Das fettgedruckte ist interessant. Ist ja momentan der Bringer, die am Besten ansprechenden Patienten bestimmen zu können. Die liefern das Diagnostic-tool gleich mit. Sollten wir auch mal versuchen..
Thread abonnieren
